Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Perry Elliott

Showing results (91-100 of 156) with videos related to

Pageof 16
Sort By:
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|July 29, 2010
Heart Rhythm UK position statement on clinical indications for implantable cardioverter defibrillators in adult patients with familial sudden cardiac death syndromesClifford J Garratt, Perry Elliott, Elijah Behr, et al.
JACC. Heart Failure|December 14, 2020
Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACTClaudio Rapezzi, Perry Elliott, Thibaud Damy, et al.
European Heart Journal|October 6, 2007
Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial DiseasesPerry Elliott, Bert Andersson, Eloisa Arbustini, et al.
Kardiologia Polska|July 18, 2008
[Classification of the cardiomyopathies]Perry Elliott, Bert Andersson, Eloisa Arbustini, et al.
JACC. Heart Failure|September 25, 2025
Pathophysiology and Therapeutic Needs in Nonobstructive Hypertrophic CardiomyopathyMilind Y Desai, Niccolo Maurizi, Elena Biagini, et al.
European Journal of Heart Failure|July 18, 2024
Safety and efficacy of aficamten in patients with non-obstructive hypertrophic cardiomyopathy: A 36-week analysis from FOREST-HCMAhmad Masri, Roberto Barriales-Villa, Perry Elliott, et al.
The American Journal of Cardiology|August 19, 2007
Prevalence and clinical significance of cardiovascular abnormalities in patients with the LEOPARD syndromeGiuseppe Limongelli, Giuseppe Pacileo, Bruno Marino, et al.
ESC Heart Failure|August 15, 2024
Characterization and natural history of patients with LMNA-related dilated cardiomyopathy in the phase 3 REALM-DCM trialPablo Garcia-Pavia, Neal K Lakdawala, Gianfranco Sinagra, et al.
European Heart Journal|September 9, 2010
Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial DiseasesPhilippe Charron, Michael Arad, Eloisa Arbustini, et al.
Circulation. Heart Failure|July 9, 2024
REALM-DCM: A Phase 3, Multinational, Randomized, Placebo-Controlled Trial of ARRY-371797 in Patients With Symptomatic <i>LMNA</i>-Related Dilated CardiomyopathyPablo Garcia-Pavia, Jose Fernando Rodriguez Palomares, Gianfranco Sinagra, et al.
Pageof 16

Showing results (91-100 of 156) with videos related to

Sort By:
Pageof 16
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|July 29, 2010
Heart Rhythm UK position statement on clinical indications for implantable cardioverter defibrillators in adult patients with familial sudden cardiac death syndromesClifford J Garratt, Perry Elliott, Elijah Behr, et al.
JACC. Heart Failure|December 14, 2020
Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACTClaudio Rapezzi, Perry Elliott, Thibaud Damy, et al.
European Heart Journal|October 6, 2007
Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial DiseasesPerry Elliott, Bert Andersson, Eloisa Arbustini, et al.
Kardiologia Polska|July 18, 2008
[Classification of the cardiomyopathies]Perry Elliott, Bert Andersson, Eloisa Arbustini, et al.
JACC. Heart Failure|September 25, 2025
Pathophysiology and Therapeutic Needs in Nonobstructive Hypertrophic CardiomyopathyMilind Y Desai, Niccolo Maurizi, Elena Biagini, et al.
European Journal of Heart Failure|July 18, 2024
Safety and efficacy of aficamten in patients with non-obstructive hypertrophic cardiomyopathy: A 36-week analysis from FOREST-HCMAhmad Masri, Roberto Barriales-Villa, Perry Elliott, et al.
The American Journal of Cardiology|August 19, 2007
Prevalence and clinical significance of cardiovascular abnormalities in patients with the LEOPARD syndromeGiuseppe Limongelli, Giuseppe Pacileo, Bruno Marino, et al.
ESC Heart Failure|August 15, 2024
Characterization and natural history of patients with LMNA-related dilated cardiomyopathy in the phase 3 REALM-DCM trialPablo Garcia-Pavia, Neal K Lakdawala, Gianfranco Sinagra, et al.
European Heart Journal|September 9, 2010
Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial DiseasesPhilippe Charron, Michael Arad, Eloisa Arbustini, et al.
Circulation. Heart Failure|July 9, 2024
REALM-DCM: A Phase 3, Multinational, Randomized, Placebo-Controlled Trial of ARRY-371797 in Patients With Symptomatic <i>LMNA</i>-Related Dilated CardiomyopathyPablo Garcia-Pavia, Jose Fernando Rodriguez Palomares, Gianfranco Sinagra, et al.
Pageof 16